Skip to main content
Defiance International

Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD.

In vivo/preclinical record. Hepatology communications, 2024.

  • Animal
  • 2024

Authorship

Exact sentences from the abstract. No machine-written text is on this page. No person reviewed it.

Source: the abstract of PMID 39761015. Checked Verification: Evidence verified by machine against declared source

This study and its findings belong to the authors cited. Defiance International, a supplier of chemical sequences for research use, keeps this record and makes no claim from its findings.

Verify a lot

Evidence verified by machine against declared source

Open declared source

Key facts

Design
Not reported
System
Animal
Scale
Average based on n = 6 in each group.
Comparator
None reported
Journal
Hepatology communications
Year
2024
PMID
39761015
Verification
Evidence verified by machine against declared source The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Full-text availability
Abstract only

Technical summary

Research question

Given the described hepatoprotective role of IL-22, we hypothesize that modulation of this neuroimmune circuit could potentially be an innovative approach for the control of liver steatosis.

Participants or experimental system

We used a model of diet-induced MASLD by exposing mice to a high-fat diet (HFD) for 16 weeks, when the development of liver steatosis was first observed in our animals.

Study scale

Average based on n = 6 in each group.

Outcomes examined

We characterized IL-22 production by intestinal ILC3 at this dietary endpoint.

Key findings

Production of IL-22 by intestinal ILC3 is reduced in steatotic mice that were exposed to an HFD for 16 weeks.

Not reported in the declared source: Methods, Study design, Comparator. Not published in this record: Intervention or exposure.

Limitations and uncertainty

Not reported in the declared source.

Cite

Cite the study

Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD.
Nguyen HH, Talbot J, Li D et al. Hepatology communications. 2024. PMID 39761015

The study and its abstract belong to their authors and publisher. Cite them for anything the study found.

Report an error

If a sentence on this record does not match the abstract, tell us which one. A report starts an automatic re-check by machine. No person reads the record first.

The form takes a sentence and your note. It asks for no name and no address, and we store neither. Do not put personal details in the note.

The report form runs in the interactive page. Open this record with scripts enabled to send a report.

Corrections on this record

No correction has been recorded for this record.

Method sheet

No machine-drafted summary is published on this record. Any section shown is the abstract’s own sentence, printed as issued.